MedPath

Chinese Firms Expand Solo Global Phase III Activity Including US Sites

In 2024, Chinese companies have initiated seven global Phase III trials, including sites in the US, with BeiGene, Genfleet, and InnoCare planning to add four more studies.

Throughout 2024, Chinese firms as sole sponsors initiated a total of seven global Phase III trials that include US sites. BeiGene, Genfleet, and InnoCare are expected to add four similar studies this year. This expansion signifies a growing presence and capability of Chinese pharmaceutical companies in conducting high-stakes clinical trials on a global scale, particularly in the competitive US market.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Medipost Expands in US and Canada; Plans US Phase III of Cartistem

Medipost is expanding its presence in the US and Canada and is planning to initiate a Phase III clinical trial of Cartistem in the US, as part of its growth strategy in the North American market.

Gyre Therapeutics Anticipates Key Data Readouts and Product Launches in 2025

Gyre Therapeutics expects topline results from its Phase 3 trial of F351 for Chronic Hepatitis B-associated liver fibrosis in China during Q1 2025.

Insilico Medicine Advances with Generative AI in Drug Discovery

Insilico Medicine, leveraging generative AI for drug discovery, is nearing completion of its phase-one clinical trials in Australia and China, with results expected early next year. The company is open to partnerships for phase-two trials, considering China a logical market due to rapid enrolment and improved clinical trial data quality. Insilico, founded in 2014, generates revenue from drug candidates and AI software services, with last year's revenue at US$51 million, projected to double this year.

Nicox's NCX 470 Phase 3 Glaucoma Trial Fully Enrolled in China Ahead of Schedule

Nicox SA announced its Denali Phase 3 trial of NCX 470 for open-angle glaucoma or ocular hypertension is fully enrolled in China, accelerating the overall trial timeline.

Roche's Vabysmo Gains Reimbursement in China, Eyes Expansion in Asia

Roche's Vabysmo will be included in China's National Reimbursement Drug List (NRDL) from 2025 to 2026, covering three ophthalmic indications.

Omics-Based Clinical Trials Market to Reach $70.92 Billion by 2034, Driven by Personalized Medicine and Oncology

The omics-based clinical trials market is projected to reach USD 70.92 billion by 2034, driven by the increasing adoption of personalized medicine.

Gilead Sciences Showcases Innovative Therapies and R&D Expansion at CIIE

Gilead Sciences debuted its new therapy for primary biliary cholangitis and highlighted Phase 3 trial results for its HIV-1 capsid inhibitor at the China International Import Expo.

Lenz Therapeutics' LNZ100 Demonstrates Positive Phase 3 Results in China for Presbyopia

Lenz Therapeutics and CORXEL announced positive topline data from a China Phase 3 trial of LNZ100, an aceclidine-based eye drop, for presbyopia treatment.

Nuance Pharma Completes Phase 3 Trial Recruitment of Ensifentrine for COPD in China

Nuance Pharma has completed patient recruitment for the ENHANCE-CHINA phase 3 trial evaluating ensifentrine for COPD maintenance treatment.

Greenwich LifeSciences' Flamingo-01 Trial Expands into Europe and Broadens Patient Enrollment

Greenwich LifeSciences' Flamingo-01 Phase III trial, evaluating GLSI-100 for breast cancer recurrence prevention, has been approved for expansion into Europe, including Spain, France, Germany, Italy, and Poland.

Reference News

[1]
Chinese Firms Expand Solo Global Phase III Activity Including US Sites
insights.citeline.com · Jan 9, 2025

In 2024, Chinese companies sponsored seven global Phase III trials with US sites. BeiGene, Genfleet, and InnoCare plan t...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy